GlassScriptPhysician profile
Gary Blair Moss
NPI 1588665137
$68,544.62
in general payments reported to CMS, 2019-2025
44 companies · $4,982 in 2025
The $4,982 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $6,585 · 2021: $9,289 · 2022: $7,954 · 2023: $9,047 · 2024: $13K · 2025: $4,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $11K · Travel and Lodging: $747 · Education: $70.55 · Consulting Fee: $18.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,600.00 |
| Food and Beverage | $10,538.38 |
| Travel and Lodging | $747.23 |
| Education | $70.55 |
| Consulting Fee | $18.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39,328.81 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $8,935.65 | 2019-2025 | Dupixent |
| Genzyme Corporation | $3,617.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,410.12 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $2,282.95 | 2019-2025 | Xolair |
| Csl Behring | $2,111.73 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $1,141.54 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Grifols USA, LLC | $1,007.12 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $901.18 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $708.43 | 2021-2025 | Orladeyo, Orladeyo |
| Kaleo, INC. | $660.14 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $597.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $534.73 | 2019-2025 | |
| Pharming Healthcare, INC. | $509.24 | 2019-2025 | Ruconest, Joenja |
| Amgen INC. | $462.88 | 2021-2025 | Tezspire |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $439.78 | 2019-2023 | Xolair |
| Abbvie INC. | $360.31 | 2021-2024 | |
| Octapharma USA, INC. | $261.65 | 2019-2025 | Cutaquig |
| Regeneron Pharmaceuticals, INC. | $244.56 | 2021-2023 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $235.96 | 2019-2022 | |
| Alk-Abello, INC | $182.41 | 2019-2023 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
| Phadia US INC. | $168.20 | 2022-2024 | Immunocap |
| Greer Laboratories, INC. | $153.85 | 2019-2024 | Oralair |
| Ars Pharmaceuticals Operations, INC. | $149.67 | 2025 | Neffy |
| Medtronic, INC. | $138.42 | 2023 | Nuvent |
| Incyte Corporation | $113.77 | 2021-2025 | Opzelura |
| Blueprint Medicines Corporation | $112.63 | 2023-2025 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $109.00 | 2025 | Dawnzera |
| Shire North American Group INC | $95.46 | 2019 | |
| Aimmune Therapeutics, INC. | $85.47 | 2021-2022 | |
| Seqirus USA INC | $66.68 | 2022-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Hikma Pharmaceuticals USA | $57.17 | 2023-2024 | Ryaltris |
| Bio Products Laboratory USA, INC. | $54.89 | 2021-2022 | |
| Biocryst Pharmaceuticals, INC. | $53.36 | 2020 | |
| Sanofi-Aventis U.S. LLC | $42.00 | 2019 | |
| Galderma Laboratories, L.P. | $32.32 | 2024-2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $30.95 | 2021-2023 | |
| Sanofi Pasteur INC. | $28.88 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.63 | 2021 | |
| Leo Pharma INC. | $24.61 | 2024 | Adbry |
| Adma Biomanufacturing LLC | $18.83 | 2025 | |
| Kedrion Biopharma, INC. | $17.26 | 2024 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
| Jubilant Hollisterstier LLC | $16.98 | 2025 | |
| Horizon Therapeutics Plc | $15.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.